(MENAFN- GlobeNewsWire - Nasdaq) The Molecular Oncology Diagnostics Market is set for significant growth, driven by increased cancer incidence and demand for early detection. Opportunities include advancements like next-generation sequencing, AI integration for faster data analysis, and personalized medicine. Challenges remain with high costs and accessibility, but policy support and innovation may bridge gaps.Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.
The Molecular Oncology Diagnostics Market was valued at USD 3.54 Billion in 2024, and is expected to reach USD 7.84 Billion by 2030, rising at a CAGR of 14.17%
The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease.
This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging regions.
Key Market Drivers
Increasing Global Cancer Incidence and Demand for Early Detection
The rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms appear.
Technologies like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer burden.
Key Market Challenges
High Cost and Limited Accessibility of Advanced Diagnostic Technologies
Despite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare access.
Challenges include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular diagnostics.
Key Market Trends
Integration of Artificial Intelligence and Machine Learning in Molecular Diagnostics
A transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual methods.
These technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH's Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the globe.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $3.54 Billion |
| Forecasted Market Value (USD) by 2030 | $7.84 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
Report Scope:
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.
Sysmex Corporation F. Hoffmann-La Roche Ltd. Myriad Genetics, Inc. HTG Molecular Diagnostics, Inc. Danaher Corporation QIAGEN N.V. Bio-Rad Laboratories, Inc. Agilent Technologies, Inc. Illumina, Inc. Bayer AG
Molecular Oncology Diagnostics Market, By Product Type:
Instruments Kits and Assays Software
Molecular Oncology Diagnostics Market, By Technology:
Fluorescence In-Situ Hybridization (FISH) Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Immunohistochemistry (IHC) Flow Cytometry Other Technologies
Molecular Oncology Diagnostics Market, By Application:
Molecular Oncology Diagnostics Market, By Cancer Type:
Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors) Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)
Molecular Oncology Diagnostics Market, By End User:
Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes
Molecular Oncology Diagnostics Market, By Region:
North America United States Mexico Canada Europe France Germany United Kingdom Italy Spain Asia-Pacific China India South Korea Japan Australia South America Brazil Argentina Colombia Middle East and Africa South Africa Saudi Arabia UAE
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Molecular Oncology Diagnostics Market
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN06062025004107003653ID1109645042
Comments
No comment